--- title: "The Stock Connect Innovative Drug ETF E Fund (159316) attracted over 17 million in net inflows yesterday." type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/39470042.md" description: "As of 11:06, among the top ten constituent stocks of the Hang Seng Stock Connect Innovative Medicine Index, Akeso Inc. rose 1.78%, CSPC Pharmaceutical Group Ltd. fell 0.73%, BeiGene, Ltd. rose 0.93%, Sino Biopharmaceutical Ltd. rose 1.57%, Innovent Biologics, Inc. rose 1.61%, Hansoh Pharmaceutical Group Company Ltd. rose 1.23%, 3SBio Inc. rose 0.93%, Kelun-Biotech Biopharmaceutical Co., Ltd. - B rose 1.46%, China Medical System Holdings Ltd. fell 0.08%, Ascentage Pharma Group International - B rose 3.61%. The E Fund Hang Seng Stock Connect Innovative Medicine ETF (159316) tracks the Hang Seng Stock Connect Innovative Medicine Index..." datetime: "2026-03-24T04:45:54.000Z" locales: - [en](https://longbridge.com/en/topics/39470042.md) - [zh-CN](https://longbridge.com/zh-CN/topics/39470042.md) - [zh-HK](https://longbridge.com/zh-HK/topics/39470042.md) author: "[同壁财经](https://longbridge.com/en/profiles/26505347.md)" --- # The Stock Connect Innovative Drug ETF E Fund (159316) attracted over 17 million in net inflows yesterday. As of 11:06, among the top ten constituent stocks of the Hang Seng Stock Connect Innovative Medicine Index, Akeso Inc. rose 1.78%, CSPC Pharmaceutical Group fell 0.73%, BeiGene Ltd. rose 0.93%, Sino Biopharmaceutical Ltd. rose 1.57%, Innovent Biologics, Inc. rose 1.61%, Hansoh Pharmaceutical Group Company Limited rose 1.23%, 3SBio Inc. rose 0.93%, Kelun-Biotech Pharmaceutical Co., Ltd. - B rose 1.46%, China Medical System Holdings Ltd. fell 0.08%, Ascentage Pharma Group International - B rose 3.61%. The E Fund Hang Seng Stock Connect Innovative Medicine ETF (159316) tracks the Hang Seng Stock Connect Innovative Medicine Index and has been favored by capital, attracting over 17 million in net inflows yesterday and over 160 million in the past 20 days. Recently, domestic innovative drugs have disclosed excellent clinical data at multiple academic conferences and in journals. A team from the Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, in collaboration with Shanghai Changzheng Hospital, recently achieved islet function restoration and autonomous blood glucose regulation in type 1 diabetes patients for the first time internationally through minimally invasive transplantation of regenerated islets (E-islet) derived from autologous and allogeneic stem cells. The related findings have been published online in the international academic journal \*The Lancet Diabetes & Endocrinology\*. Additionally, Ascentage Pharma Group International announced that it will present four latest preclinical progress reports at the 2026 American Association for Cancer Research Annual Meeting. Shenwan Hongyuan pointed out that after more than a decade of development, the R&D style of China's innovative drugs is shifting from "fast-following" to "innovation-leading," which may guide the global new drug R&D landscape in the future. This report reviews several cutting-edge technology platforms in the global new drug field, including molecular glues, small nucleic acids, in vivo CART, etc., and finds that Chinese companies have deep involvement in all of them. These emerging technology platforms have significant advantages in target druggability, R&D efficiency, and production costs, making them the key investment direction for the next stage of innovative drugs. The E Fund Hang Seng Stock Connect Innovative Medicine ETF (159316) is currently the only ETF product in the market tracking the Hang Seng Innovative Medicine Index, possessing high elasticity and scarcity, helping investors better grasp the investment opportunities in this round of Hong Kong stock innovative medicine. Related Products: E Fund Hang Seng Stock Connect Innovative Medicine ETF (159316) E Fund Hang Seng Stock Connect Innovative Medicine Connect Fund A (024328) E Fund Hang Seng Stock Connect Innovative Medicine Connect Fund C (024329) ### Related Stocks - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) - [688235.CN](https://longbridge.com/en/quote/688235.CN.md) - [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md) - [00867.HK](https://longbridge.com/en/quote/00867.HK.md) - [06990.HK](https://longbridge.com/en/quote/06990.HK.md) - [ONC.US](https://longbridge.com/en/quote/ONC.US.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [06855.HK](https://longbridge.com/en/quote/06855.HK.md) - [06806.HK](https://longbridge.com/en/quote/06806.HK.md) - [CART.US](https://longbridge.com/en/quote/CART.US.md) - [03692.HK](https://longbridge.com/en/quote/03692.HK.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [01093.HK](https://longbridge.com/en/quote/01093.HK.md) - [01177.HK](https://longbridge.com/en/quote/01177.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) - [000166.CN](https://longbridge.com/en/quote/000166.CN.md) - [8A8.SG](https://longbridge.com/en/quote/8A8.SG.md) - [AAPG.US](https://longbridge.com/en/quote/AAPG.US.md)